Invivo Therapeutics (NVIV) and Its Peers Head to Head Survey
Invivo Therapeutics (NASDAQ: NVIV) is one of 79 public companies in the “Advanced Medical Equipment & Technology” industry, but how does it contrast to its peers? We will compare Invivo Therapeutics to similar companies based on the strength of its analyst recommendations, dividends, institutional ownership, profitability, earnings, valuation and risk.
This table compares Invivo Therapeutics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Invivo Therapeutics Competitors||-151.89%||-22.51%||-8.72%|
This is a summary of recent recommendations for Invivo Therapeutics and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Invivo Therapeutics Competitors||278||1911||3405||109||2.59|
Invivo Therapeutics currently has a consensus target price of $6.00, suggesting a potential upside of 589.66%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 0.06%. Given Invivo Therapeutics’ higher possible upside, equities analysts clearly believe Invivo Therapeutics is more favorable than its peers.
Insider & Institutional Ownership
12.8% of Invivo Therapeutics shares are owned by institutional investors. Comparatively, 51.8% of shares of all “Advanced Medical Equipment & Technology” companies are owned by institutional investors. 3.9% of Invivo Therapeutics shares are owned by insiders. Comparatively, 18.4% of shares of all “Advanced Medical Equipment & Technology” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Risk and Volatility
Invivo Therapeutics has a beta of 3.2, indicating that its share price is 220% more volatile than the S&P 500. Comparatively, Invivo Therapeutics’ peers have a beta of 1.21, indicating that their average share price is 21% more volatile than the S&P 500.
Valuation and Earnings
This table compares Invivo Therapeutics and its peers gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Invivo Therapeutics||N/A||-$23.43 million||-1.02|
|Invivo Therapeutics Competitors||$2.14 billion||$234.27 million||-80.96|
Invivo Therapeutics’ peers have higher revenue and earnings than Invivo Therapeutics. Invivo Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Invivo Therapeutics peers beat Invivo Therapeutics on 9 of the 12 factors compared.
Invivo Therapeutics Company Profile
InVivo Therapeutics Holdings Corp., formerly Design Source, Inc., is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company’s approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury. The Neuro-Spinal Scaffold consists of biocompatible and bioresorbable polymers, which include poly lactic-co-glycolic acid (PLGA) and Poly-L-Lysine (PLL). The Company is also evaluating other technologies and therapeutics that may be complementary to its development of the Neuro-Spinal Scaffold implant. The Company has a clinical development program for acute SCI and a preclinical development program for chronic SCI.
Receive News & Ratings for Invivo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.